Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Sales and Divestitures (2021 - 2024)

Apellis Pharmaceuticals (APLS) has 5 years of Gains from Sales and Divestitures data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 4.79% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 4.79%, while the annual FY2025 figure was $1.5 million, 4.79% up from the prior year.
  • Gains from Sales and Divestitures reached $1.5 million in Q4 2025 per APLS's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.5 million in Q4 2025 and bottomed at $129000.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $883400.0, with a median of $1.0 million recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 184.5% in 2022, then grew 4.79% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $129000.0 in 2021, then skyrocketed by 184.5% to $367000.0 in 2022, then surged by 176.57% to $1.0 million in 2023, then surged by 39.8% to $1.4 million in 2024, then grew by 4.79% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.5 million in Q4 2025, $1.4 million in Q4 2024, and $1.0 million in Q4 2023.